Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Vanguard Total Stock Market Index Fund ETF trades at $367.8. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | VTI | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $374.36 |
52-Week Low | $10.24 | $305.58 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VTI trades at $371.67, up 0.79% today, with a bullish technical outlook supported by moving averages. The ETF offers broad U.S. equity exposure across 3,400+ stocks with a minimal 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and comparisons with competing total market ETFs, reinforcing its popularity for long-term wealth building.
VTI presents a low-cost core holding for diversified U.S. stock exposure, though its neutral oscillators and elevated short-term RSI suggest near-term consolidation risks. Market volatility and economic shifts remain key headwinds, but analyst sentiment favors its long-term growth potential amid accelerating small-cap earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
